OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38443 COGENT BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Exhibit 99.1 https://files.reportify.cc/m Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 Bezuclastinib – Gastrointestinal Stromal Tumors (GIST) • Report top-line results by the end of 2025 from the pivotal Phase 3 PEAK trial. PEAK is a global, blinded, randomized clinical trial studying the combination of bezuclastinib and sunitinib versus sunitinib alone in patients with ...

• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from PEAK trial in 2nd-line GIST patients expected by end of 2025 • $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025 WALTHAM, Mass. and BOULDER, Colo., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biot ...

Group 1 - Cogent Biosciences, Inc. (COGT) is a notable stock in the Medical sector, currently ranked 2 in the Zacks Sector Rank, which evaluates the average Zacks Rank of individual stocks within the sector [2][3] - The Zacks Consensus Estimate for COGT's full-year earnings has increased by 2.6% over the past quarter, indicating a positive trend in analyst sentiment and earnings outlook [4] - COGT has achieved a year-to-date performance increase of approximately 12.3%, significantly outperforming the average gain of 5.3% in the Medical sector [4] Group 2 - Cogent Biosciences, Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 510 companies and is currently ranked 65 in the Zacks Industry Rank [6] - Stocks in the Medical - Biomedical and Genetics industry have gained about 2.9% year-to-date, showcasing COGT's superior performance within this group [6] - Another outperforming stock in the Medical sector is Cardiol Therapeutics Inc. (CRDL), which has increased by 7% year-to-date, with a consensus EPS estimate rise of 12.5% over the past three months [5][7]

Core Insights - Cogent Biosciences, Inc. is set to present a poster on bezuclastinib at the 2025 AAAAI Annual Meeting, focusing on its efficacy and safety in patients with Non-Advanced Systemic Mastocytosis [1][3] Company Overview - Cogent Biosciences specializes in developing precision therapies for genetically defined diseases, with bezuclastinib being its most advanced clinical program [4] - Bezuclastinib is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is linked to systemic mastocytosis and other cancers [4] - The company is also conducting a Phase 1 study of a novel FGFR2 inhibitor and developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [4] Presentation Details - The poster presentation titled "Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial" will take place on March 1, 2025 [3] - The session will highlight the benefits of long-term use of 100mg bezuclastinib over at least 48 weeks [2] - The presentation is scheduled for 9:45am – 10:45am PT at the San Diego Convention Center [3]

Cogent Biosciences Inc (COGT) Conference February 05, 2025 09:30 AM ET Company Participants Michael Schmidt - Senior Managing Director, Equity ResearchAndrew Robbins - CEO Michael Schmidt Welcome to this next fireside chat with Cogen Biosciences. With us today, we have Andrew Robbins, President and CEO. I'm Michael Schmidt, Senior Biotech Analyst with Guggenheim, and it is a great pleasure to talk to you today. Andrew, welcome, and thanks for joining us. Andrew Robbins Thanks, Michael. Great to be here. Mic ...

Core Insights - Cogent Biosciences, Inc. is participating in the Guggenheim SMID Cap Biotech Conference on February 5, 2025, at 9:30 a.m. ET [1] - The company focuses on developing precision therapies for genetically defined diseases, with its most advanced clinical program being bezuclastinib, a selective tyrosine kinase inhibitor [3] Company Overview - Cogent Biosciences is based in Waltham, MA, and Boulder, CO, and is dedicated to creating targeted therapies for serious diseases driven by genetic mutations [3] - The company is currently conducting a Phase 1 study of a novel FGFR2 inhibitor and is developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [3] Event Information - A live webcast of the conference participation can be accessed on Cogent's Investors & Media page, with a replay available for 30 days post-event [2]

Company Overview - Cogent Biosciences (NASDAQ: COGT) is a clinical-stage biotech company focused on genetically defined diseases, with its lead candidate Bezuclastinib [1] - Bezuclastinib is currently in 3 ongoing late-stage trials targeting AdvSM, non-AdvSM, and GIST [1] Clinical Trials - The company's success hinges on the outcomes of its 3 late-stage trials for Bezuclastinib [1] Author Background - The author, Myriam Hernandez Alvarez, holds multiple degrees including a Ph.D. in computer applications and collaborates professionally with Edgar Torres H [1]

Core Insights - Cogent Biosciences anticipates 2025 to be a transformational year, with plans to report top-line results from three registration-directed studies of bezuclastinib and submit its first New Drug Application (NDA) by the end of the year [2][9] Milestones for 2025 - The company plans to report top-line results from the SUMMIT trial for Non-Advanced Systemic Mastocytosis (NonAdvSM) in July 2025 [8][9] - Top-line results from the pivotal Phase 3 PEAK trial for gastrointestinal stromal tumors (GIST) are expected by the end of 2025 [4][9] - The APEX trial for Advanced Systemic Mastocytosis (AdvSM) will report results in the second half of 2025 [9] - An Expanded Access Program (EAP) for bezuclastinib will be initiated in Q1 2025 for eligible SM and GIST patients [5] Pipeline Development - The ongoing Phase 1 trial of CGT4859, a selective FGFR2 inhibitor, aims to explore safety and tolerability in patients with FGFR mutations [6] - The company plans to submit IND applications for CGT4255, a selective ErbB2 inhibitor, and CGT6737, a potent allosteric inhibitor of PI3Kα, during 2025 [7][10] Financial Position - Cogent Biosciences has a strong balance sheet, positioning the company well for its transition into a commercial-stage entity [2]

Core Points - Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases [3] - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 [1] - The most advanced clinical program is bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation [3] - Bezuclastinib is designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST) [3] - Cogent is also developing a portfolio of targeted therapies for mutations in FGFR2, ErbB2, PI3Kα, and KRAS [3] Company Information - Cogent Biosciences is headquartered in Waltham, MA, and Boulder, CO [3] - The company provides a live webcast of its presentations on its Investors & Media page [2] - A replay of the webcast will be available for 30 days after the event [2] Contact Information - Christi Waarich is the Senior Director of Investor Relations [4] - Contact details include email: christi.waarich@cogentbio.com and phone: 617-830-1653 [4]